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Abstract
Background: Despite medical advances, mortality in infective endocarditis (IE) is still very high. Previous studies on
prognosis in IE have observed conflicting results. The aim of this study was to identify predictors of in-hospital
mortality in a large multicenter cohort of left-sided IE.
Methods: An observational multicenter study was conducted from January 1984 to December 2006 in seven
hospitals in Andalusia, Spain. Seven hundred and five left-side IE patients were included. The main outcome
measure was in-hospital mortality. Several prognostic factors were analysed by univariate tests and then by
multilogistic regression model.
Results: The overall mortality was 29.5% (25.5% from 1984 to 1995 and 31.9% from 1996 to 2006; Odds Ratio 1.25;
95% Confidence Interval: 0.97-1.60; p = 0.07). In univariate analysis, age, comorbidity, especially chronic liver disease,
prosthetic valve, virulent microorganism such as Staphylococcus aureus, Streptococcus agalactiae and fungi, and
complications (septic shock, severe heart failure, renal insufficiency, neurologic manifestations and perivalvular
extension) were related with higher mortality. Independent factors for mortality in multivariate analysis were:
Charlson comorbidity score (OR: 1.2; 95% CI: 1.1-1.3), prosthetic endocarditis (OR: 1.9; CI: 1.2-3.1), Staphylococcus
aureus aetiology (OR: 2.1; CI: 1.3-3.5), severe heart failure (OR: 5.4; CI: 3.3-8.8), neurologic manifestations (OR: 1.9; CI:
1.2-2.9), septic shock (OR: 4.2; CI: 2.3-7.7), perivalvular extension (OR: 2.4; CI: 1.3-4.5) and acute renal failure (OR: 1.69;
CI: 1.0-2.6). Conversely, Streptococcus viridans group etiology (OR: 0.4; CI: 0.2-0.7) and surgical treatment (OR: 0.5; CI:
0.3-0.8) were protective factors.
Conclusions: Several characteristics of left-sided endocarditis enable selection of a patient group at higher risk of
mortality. This group may benefit from more specialised attention in referral centers and should help to identify
those patients who might benefit from more aggressive diagnostic and/or therapeutic procedures.
Background
The diagnostic and therapeutic advances of recent years
have only marginally reduced mortality associated with
infective endocarditis (IE). Thus, a 30% mortality rate
was reported after the introduction of antimicrobial
therapy [1] but 50 years later, despite the introduction
of new antimicrobial agents and advances in surgical
therapy, and even though some recent publications
found mortality rates lower than 20%[2,3], it remains
around 20-40% in most series [4,5].
During the past few years, several published epidemio-
logical studies have identified a number of prognostic
factors related to higher mortality, such as advanced age
[6,7], female gender [6], prosthetic valve endocarditis
[6,7], Staphylococcus aureus aetiology [6-10], comorbid-
ity [6,9], analytical data (leucocytosis [11], hypoalbumi-
nemia [11], C-reactive protein values [12] and elevated
ERS [7]), and the development of various complications
(heart failure [6-9,12,13], cerebral embolism [7,10,12]
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extension [7]). However, studies investigating prognostic
factors for IE frequently have methodological flaws since
they are based on short retrospective series, the experi-
ence of a single hospital, or use non-uniform diagnostic
criteria. Moreover, many of these studies are performed
in referral centers, where the most complicated cases
are usually treated [14]. More accurate information may
be obtained from prospective multicenter studies, in
which it is possible to include a large number of cases
based on strict diagnostic criteria. Knowledge of poten-
tially modifiable risk factors should help to identify
those patients who might benefit from more aggressive
diagnostic and/or therapeutic procedures [15]. Our
objective was to investigate factors associated with a
worse prognosis in a multicenter cohort of left-sided IE
patients.
Methods
Study design and patients
All patients diagnosed of IE in seven hospitals in Anda-
lusia (South of Spain) were consecutively registered in a
uniform database from January 1984 throughout
December 2006. Five are tertiary referral hospitals for
cardiac surgery and 2 are community hospitals; the lat-
ter transferred patients evaluated as being at higher risk
for mortality to the referral centres. All cases of left-
sided IE defined according to Duke criteria [16] with
later modifications [17] for definite and possible IE were
included. Patients registered before 1994 were retrospec-
tively evaluated for diagnostic criteria. In the case of
relapses, only the first episode was included. Cases with
insufficient follow-up (not longer than one month) were
excluded.
Variables and definitions
Data were recorded prospectively by members of the
Infectious Diseases services or units in the participating
centres using a structured questionnaire and introduced
into a common database. The cases were detected from
routine review of microbiology, echocardiography and
surgery reports. The primary outcome measure was
overall mortality during hospitalisation (in-hospital
death). All cases with no signs of infection and a nega-
tive post-antimicrobial treatment culture were consid-
ered cured. Relapses, defined as an IE episode occurring
within 6 months of a previous one and caused by the
same microorganism, were also recorded. Recurrence
was defined as a new IE episode in the same patient and
related to a different microorganism. The following
independent variables were recorded: age, sex, health
care-associated acquisition, type and severity of underly-
ing comorbidity evaluated according to the age-adjusted
Charlson index [18], duration of symptoms before diag-
nosis, septic shock, heart failure, embolism, neurologic
manifestations, acute renal failure, echocardiographic
findings (vegetations and size, abscess, prosthetic dehis-
cence and valvular dysfunction), microbiologic data
(microorganisms isolated from blood cultures and/or
valve tissues, and serologic tests), and treatment (medi-
cal and surgical). For analysis purposes, the study period
was arbitrary divided in two: 1984 - 1995 and 1996 -
2006.
The additive euroSCORE index [19] were calculated
for operative risk evaluation in every patient. Predispos-
ing valvulopathy was defined as any previous valvular
heart lesion that predispose to IE. Prosthetic endocardi-
tis was considered as early if it occurred within one year
of valve implantation and late otherwise. Heart failure
was defined according to Framingham’s criteria [20] and
was evaluated at admission and during evolution. Septic
shock was defined according to standard criteria [21].
Perivalvular extension was defined as the presence of an
abscess and/or fistula and/or pseudoaneurism diagnosed
by echocardiogram, in surgery or at autopsy. A major
symptomatic embolism was considered if the central
nervous system, spleen or extremities were affected.
Neurologic manifestations were considered only in
patients with clinical manifestations related to encepha-
lopathy, meningitis, cerebral infarct or a haemorrhage,
and demonstrated by cerebrospinal fluid analysis, radi-
ological test or at autopsy. Severe renal insufficiency was
defined as a serum creatinin level >2.5 mg/dl. Left-sided
IE were considered nosocomially acquired using pre-
viously published criteria [22]. After 1994 transesophagic
echocardiography (TEE) was performed in cases with a
high clinical probability of IE when transthoracic echo-
chardiography (TTE) was not diagnostic, and routinely
in prosthetic IE or when cardiac complications were
suspected.
This study was approved by ethical and research com-
mittees of all participating hospitals.
Statistical analysis
The association of the different variables with the out-
come was firstly analysed by univariate analysis. Contin-
uous variables were expressed like mean ± standard
deviation or like median and interquartile rank in case
of abnormal distribution and were analysed using the
Student’s T test or the Mann-Whitney U test as appro-
priate. Categorical variables were expressed like absolute
numbers and proportion of cases and were compared
using the chi-squared or Fisher’s test when appropriate.
Relative risks with 95% confidence interval for mortality
were calculated. Then, multivariate analysis was per-
formed using logistic regression. The multivariate model
was built including all variables with a significant asso-
ciation in univariate analysis (p < 0.05) and those con-
sidered potentially clinically relevant; modification
effects between variables were also studied. The
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backward procedure. All statistical studies were per-
formed using SPSS software (v12.0, Chicago, IL, USA).
Results
General features of the cohort
Seven hundred and five case-patients of left-sided IE
were included in the study. Only other 8 patients were
excluded because insufficient evolution data. Among
included cases, 624 (88%) were considered as definite
and 81 (12%) as possible IE. Mean (± SD) post-hospitali-
sation follow-up was 15.75 ± 25.05 months (range: 1-
192). The median age of the patients was 56 years
(interquartile rank from 41 to 68 years), only 5 patient
were ≤ 15 years old. Four hundred and eighty six (69%)
patients were male. Native valves were affected in 534
(76%) cases. Of 171 patients (24%) with prosthetic IE,
69 were considered early and 102 late. The aortic valve
was affected in 320 (45%) cases, the mitral valve in 299
(42%), and both valves were affected in 86 (11%)
patients. Globally, 488 (69%) had a predisposing valvulo-
p a t h yf o rI Ea n d5 7( 8 % )h a ds u f f e r e da tl e a s to n ep r e -
vious episode of IE. The mean (± SD) age-adjusted
Charlson index was 1.84 ± 2.27 (range: 0-10), and the
most frequent underlying diseases were: diabetes melli-
tus (35 patients, 5%), non-valvular heart diseases (32
patients, 5%), chronic liver diseases (32 patients 5%);
neoplasia (28 patients, 4%); chronic renal insufficiency
(24 patients, 3%); and chronic lung disease (16 patients,
2%). Forty-six patients (7%) were intravenous drug
abusers.
Aetiology was established by isolating the causative
microorganism from blood culture in 598 (85%)
patients, a surgically-explanted valve culture in 70 (10%)
and by serologic test in 35 (5%). Streptococcus viridans
group was the most frequent microorganism isolated,
followed by Staphylococcus aureus, coagulase-negatives-
taphylococci and Enterococcus spp. (table 1). In 71 cases
(10%), aetiology was unknown, because all microbiologi-
cal studies were negatives.
Echocardiography was performed on 698 patients:
TTE alone on 409 (58%), TEE alone on 16 (2%) and
both TTE and TEE on 273 patients (39%). In 7 patients,
no echocardiographic study was performed because
endocarditis was not suspected until surgery or
necropsy. Overall, TTE was diagnostic in 448 of 682
patients (66%) in which it was performed, and TEE in
251 of 289 (87%). In 156 patients where a TTE study
was not diagnostic, a TEE study obtained a defined diag-
nosis of IE in 122 (78.2%).
Many patients developed complications: 282 (40%) had
cardiac failure, 194 (27%) presented neurologic manifes-
tations, 280 (40%) had systemic embolisms (in 147
cases, the central nervous system was affected), 190
(27%) developed acute renal insufficiency, 86 (12.2%)
septic shock, and 87 (13%) perivalvular extension (peri-
valvular abscess, 70; fistula 15; and pseudoaneurism 2).
Valvular surgery was performed in 269 patients (38%).
The most frequent indications for surgery were severe
heart failure (in 171 patients, 63.5%), followed by valve
dysfunction (37 patients, 13.7%), persistent sepsis (21
patients, 7.8%), and perivalvular extension (8 patients,
2.9%). There were several indications for surgery in 27
patients (10.0%). Fifty and three (7.5%) was not operated
because of critical situation and high risk intervention.
Prognosis
Two hundred and eight patients died during their hospi-
tal stay (mortality rate, 29.5%). Relapses occurred in 17
patients (2.4%), and the 480 remaining cases (68%) were
considered cured. Principal causes of death was: heart
failure in 44 patients (21.5%) sepsis in 28 (13.4%) neuro-
logic complications in 22 (10.5%), and by several of
these complications in 71(34.1%).
The variables significantly associated with increased
mortality in univariate analysis were age, nosocomial
acquisition, severity of underlying disease, chronic liver
disease, prosthetic valve endocarditis, early prosthetic
valve endocarditis, S. aureus, Streptococcus agalactiae
and fungal aetiology, lesser duration of symptoms before
diagnosis, development of septic shock, progressive or
refractory heart failure, acute renal insufficiency, the
presence of cardiac abscess or fistula, and non per-
formed surgery although indicated because of high asso-
ciated risk (tables 2 and 3). Conversely, Streptococcus
viridans group aetiology was associated with lower mor-
tality rates. The final multivariate model is shown in
table 4; the p value of the Hosmer-Lemeshow goodness-
of-fit test for the final model was 0.514.
Discussion
Mortality rate of left-sided IE remains high. Although
rates lower than 20% have been reported [7,22,23], they
usually range between 20 and 30%[4,5] and are even
higher in some subgroups; mortality rates of 50% has
been reported in early prosthetic valve IE due to S. aur-
eus [24]. Crude mortality rate in our series was 29.5%,
an intermediate figure considering the intrinsic features
of the patients, the number of complicated cases, and
the length of the study period. Considering the evolu-
tion of mortality over time, we observed a non-signifi-
cant upward trend, probably related to an increased
percentage of cases caused by more virulent organisms
such as S. aureus, and to a higher frequency of elderly
patients with comorbidities.
Previous studies about the prognosis of IE have often
been incomplete in their collection of risk factors, have
included heterogeneous subtypes (ie, left-side and right-
side endocarditis) or have been carried out on patients
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ter cohort with multivariate analysis studies including
large numbers of patients have been reported
[6,7,9,10,13,25], of which one included only patients
admitted to the ICU [10] and another only patients with
prosthetic valve IE [12]. This prospective multicenter
study includes cases from both referral and community
hospitals. We also include IE in both prosthetic and
native valves and we have included most factors found
in previous studies, such as patient-related variables,
aetiology, and the development of different
complications.
A Charlson index of more than 2 points has been
reported to be an independent risk factor for mortality
in previous studies [6,9]. We used the age-adjusted
index on the grounds that age may be related to prog-
nosis [26] and also found it to be related with increased
risk of death. Many of our patients had more than one
underlying condition. Insulin-dependent diabetes melli-
tus has been observed to be a risk factor in one study
[27] but we did not find such association in ours. On
t h eo t h e rh a n d ,av e r yh i g hm o r t a l i t yr a t ew a sf o u n d
among patients with chronic liver disease (47%), simi-
larly to what has been reported in another Spanish ser-
ies [28].
Prosthetic valve IE, particularly early episodes and
those caused by S. aureus, are usually associated with a
worse prognosis than native valve IE [23,29]. Crude
mortality of prosthetic valve IE in our series was almost
3 times higher than for native IE, corroborating the
results of previous studies [12,29,30]. Furthermore, S.
aureus was independently associated with increased
mortality, whilst Streptoccocus viridans group was a pro-
tective factor. Our results confirm another recent colla-
borative multicenter study where mortality for IE was
higher when due to S. aureus (22.4% vs 14.6% for other
aetiologies)[30]; association of this microorganism with
life-threatening complications, such as septic shock and
neurologic manifestations have also been reported [31].
All these data emphasise the prognostic relevance of
this microorganism in IE.
Heart failure has been found to be a strong marker for
increased mortality in most studies [8]. In contrast to
Chu et al [7], we did not find heart failure at admission
to be associated with a worse prognosis. A possible
explanation for this is that heart failure at admission,
when due to treatable disorders such as arrhythmia,
fluid overload, etc, may be controlled by medical treat-
ment. On the other hand, the development of moderate
to severe heart failure during evolution was related to
increased mortality. We think that development of heart
failure during evolution is probably due in most cases to
progressive valve dysfunction, which would only be
modifiable by surgery. In fact, surgery was a protective
factor in our study. Surgical treatment was a protective
factor in only two previous studies [8,9], particularly in
complicated cases with severe heart failure [32]. The
fact that surgery is an independent protective factor for







Streptococcus viridans group 132 (25) 3 (4) 21 (21) 156 (22)
Enterococcus spp 60 (11) 6 (9) 12 (12) 78 (11)
Streptococcus bovis 18 (3) 0 1 (1) 19 (3)
Streptococcus agalactiae 12 (2) 0 3 (3) 15 (2)
Others 21 (4) 0 3 (3) 24 (3)
Staphylococci
Staphylococcus aureus 106 (21) 11 (16) 12 (14) 137 (19)
Coagulase-negative Staphylococci 45 (8) 34 (50) 23 (23) 102 (15)
Gramnegative bacilli 14 (3) 1 (2) 1 (1) 16 (2)
HACEK Group 5 (1) 0 4 (4) 9 (1)
Brucella spp 12 (2) 0 0 12 (2)
Coxiella burnetii 12 (2) 0 6 (6) 18 (3)
Fungi 5 (1) 3 (4) 1 (1) 9 (1)
Other 12 (2) 4 (6) 4 (4) 20 (3)
Polymicrobial 19 (4) 0 0 19 (3)
Unknown 53 (10) 7 (10) 11 (11) 71 (10)
Total 534 (100) 69 (100) 102 (100) 705
Data are expressed as number of cases (%).
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number of complicated cases included with heart failure
due to valvular dysfunction. However this date must be
interpreted with caution since this is an observational
study; in another recent study [8], surgery during epi-
sode of IE either was associated with better prognosis
when this variable was analysed in a multivariable
regression modelling.
The exact impact of surgical treatment in IE is contro-
versial and difficult to assess, since evidence is based in
observational studies but not in clinical trials. Some new
methods of analysis, such as the use of propensity score,
have been applied in some studies in order to improve
the control of confounding. However the results of
these studies are conflicting probably because of metho-
dological differences, as has been recently reviewed [33].





RR 95% CI p
Age (years) Mean ± SD 51.6 ± 17 58.8 ± 16 - - <0.001
Gender Male 345 (71) 141 (29) 1.07 0.76-1.52 0.367
Female 152 (69.4) 67 (30.6)
Period 1984-1995 196 (74.5) 67 (25.5) 1.25 0.97-1.60 0.070
1996-2006 301 (68.1) 141 (31.9)
Hospital Tertiary 451 (69.3) 200(30.7) 2.07 1.08-3.96 0.008
Community 46 (85.2) 8 (14.8)
Nosocomial Yes 55 (53.4) 48 (46.6) 1.75 1.37-2.24 <0.001
No 442 (73.4) 160 (26.6)
Comorbidity Yes 259 (64.4) 143 (35.6) 1.65 1.28-2.13 <0.001
No 238 (78.8) 65 (21.5)
Charlson’s index Mean ± SD 1.56 ± 2,50 ± <0.001
2.15 2.42
Diabetes mellitus Yes 24 (68.8) 11 (31.4) 1.06 0.64-1.76 0.464
No 473 (70.6) 197 (29.4)
Chronic renal insufficiency Yes 14 (58.3) 10 (41.7) 1.43 0.88-2.33 0.184
No 483 (70.9) 198 (29.1)
Chronic liver Yes 17 (53.1) 15 (46.9) 1.63 1.10-2.40 0.027
Disease No 480 (71,3) 193 (28,7)
Valve involved Aortic 223 (71.9) 118 (29.3) 1.02 0.81-1.28 0.456
Mitral 274 (69.3) 90 (29.1)
>1 valve involved Yes 49 (64.5) 27 (35.5) 1.23 0.89-1.71 0.223
No 448 (71,2) 181 (28,8)
Valve type Prosthetic 104 (60.8) 67 (39.2) 1.48 1.17-1.87 0.001
Native 393 (73.6) 141 (26.4)
Prosthetic type Early 33 (47.8) 36 (52.2) 1.93 1.48-2.50 <0.001
Late 464 (73) 172 (27)
S. aureus Yes 70 (51.1) 67 (48.7) 1.96 1.57-2.46 <0.001
No 427 (75.2) 141 (24.8)
S. viridans group Yes 140 (89.7) 16 (10.3) 0.29 0.18-0.47 <0.001
No 357 (65) 192 (35)
Coagulase-negative Staphylococci Yes 64 (62.7) 38 (37.3) 1.32 0.99-1.75 0.040
No 433 (71.8) 170 (28.2)
Enterococcus spp. Yes 52 (66.7) 26 (33.3) 1.14 0.1-1.60 0.254
No 445 (71) 182 (29)
S. agalactiae Yes 7 (46.7) 8 (53.3) 1.84 1.12-2.99 0.044
No 490 (71) 200 (29)
Fungal Yes 2 (22.2) 7 (77.8) 2.69 1.86-3.89 0.004
No 495 (71.1) 301 (28.9)
Data are expressed as number of cases (%) except when indicated.
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ciated with a worse prognosis [7,10,12]. In this study, as
found in others, about one quarter of patients developed
neurologic complications [34]. We considered this com-
plications only when it was clinically relevant, and not
only like alterations in imaging techniques. Embolic
phenomena are known to be more frequent at admis-
sion and during the first week, to occur despite proper
medical treatment, and to be associated with worse
prognosis, as was the case in our series.
Septic shock, which was developed by about 10% of
our patients, was independently associated with
increased mortality. This variable has only been studied
previously in a report detailing IE patients admitted to
the ICU [10], probably because it is not a frequent com-
plication and cannot be evaluated as an independent
risk factor in series with a low number of cases. As sep-
tic shock has been associated in general patients with
mortality rate of about 50% [35], we consider that this
variable helps to identify a high-risk subgroup of
Table 3 Univariate analysis of in-hospital-mortality: echocardiographic characteristics, complications and treatment.
Variable Alive N = 497 Deaths
N = 208
RR 95% CI P
Duration of symptoms (days) Mean ± SD 40.5 ± 84 20.3 ± 27.4 <0.001
Septic shock Yes 24 (27.9) 62 (72.1) 3.05 2.51- <0.001
No 473 (76.4) 146 (23.6) 3.70
Severe heart failure Yes 101 (57.1) 76 (42.9) 1.75 1.59- <0.001
(Admission) No 397 (75,1) 131 (24,9) 3.25
Severe heart failure Yes 150 (53.2) 132 (46.8) 2.60 2.05- <0.001
(Evolution) No 347 (82) 76 (18) 3.31
Renal insufficiency Yes 99 (52.1) 91 (47.9) 2.15 1.79- <0.001
No 397 (77.8) 113 (22.2) 2.69
Neurologic Yes 113 (57.9) 82 (42.1) 1.70 1.36- <0.001
manifestations No 384 (75.3) 126 (24.7) 2.12
Perivalvular Extension Yes 44 (51.2) 42 (48.8) 1.82 1.41-2.34 <0.001
No 453 (73.2) 166 (26.8)
Vegetations in echocardiography Present 362 (68.8) 164 (31.2) 1.29 0.95- 0.075
Absent 133 (75.4) 44 (24.6) 1.68
Vegetations > 20 mm* Yes 35 (63.6) 20 (36.4) 1.40 0.96- 0.070
No 402 (74) 141 (26) 2.04
Additive euro SCORE Mean ± SD 7.86 ± 3.65 12.39 ± 3.07 <0.001
Surgical treatment Yes 180 (67.2) 88 (32.8) 1.19 0.95- 0.07
No 317 (72.5) 120 (27.5) 1.50
Not performed surgery¶ Yes 7 (13.2) 46 (86.8) 19,8 8.80- <0.001
No 490 (75.2) 162(24.8) 7 44.89
Data are expressed as number of cases (%) except when indicated.
* Size of vegetations measured in 598 patients. ¶Surgery indicated but not performed
Table 4 Multivariate analysis of prognostic factors of in-hospital mortality.
Variable b OR 95% CI P
Charlson comorbidity score 0.217 1.24 1.14-1.35 <0.001
Prosthetic endocarditis 0.688 1.99 1.26-3.14 0.003
S. aureus aetiology 0.760 2.13 1.30-3.50 0.002
S. viridans group aetiology -0.88 0.41 0.22-0.76 0.005
Severe heart failure (Evolution) 1.691 5.42 3.31-8.86 <0.001
Neurologic manifestation 0.657 1.93 1.24-2.99 0.001
Septic shock 1.445 4.24 2.33-7.70 <0.001
Perivalvular extension 0.914 2.49 1.37-4.53 0.003
Acute renal insufficiency 0.525 1.69 1.09-2.60 0.017
Surgical treatment -0.685 0.50 0.30-0.84 0.010
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such as early identification of severe sepsis and trigger-
ing evidence-based protocolised care [36].
Vegetations observed in echocardiography have been
previously associated to a poor outcome [8] although
o n es t u d yf o u n do n l yl a r g e - s i z e dv e g e t a t i o n st ob ea n
independent prognostic factor [6]. In our study, a vege-
tation size of >20 mm almost reached statistical signifi-
cance in univariate analysis b u td i dn o ti nm u l t i v a r i a t e
analysis; a limitation of our study is that size of vegeta-
tions was not measured in all cases.
Perivalvular extension of infection (abscess and/or fis-
tula) has traditionally been seen as an unfavourable
prognostic factor [7,37] although less so in more recent
studies [25,38]. As in another recent large study [7] we
found this complication to be an independent risk factor
for mortality, which may be related to a higher post-sur-
gical mortality associated with the intrinsic technically
difficulties of these cases. This is a variable that identify
another high-risk subgroup of patients, and must be
suspected in presence of risk factors for this complica-
tions like prosthetic IE and aortic localization [25].
Our study have some limitations: First, changes in the
clinical management of IE m a yh a v eo c c u r r e dd u r i n g
the long study period, although the inclusion of this
variable in the multivariate model did not affect the
results. Second, the majority of cases were included
from referral centers so that the percentage of compli-
cated cases may have been overestimated. However,
other multicenter studies only include cases from refer-
ence centers and, even if represented by a small percen-
tage, our series probably better reflects the overall
clinical reality. Third, as TEE was not systematically per-
formed, evaluation of echocardiographic data (size of
vegetations, perivalvular extension) may be biased. And
fourth, it is an observational study, so some results,
such as the protective effect of surgery, must be inter-
preted cautiously.
Conclusions
We believe that our results may help identify IE patients
at increased risk of in-hospital death by using data that
are usually bedside available, which identify candidates
for a more aggressive management in referral centers,
with experience that includes active search for septic
and hemodynamic complications and early surgical
treatment when indicated.
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